Success Metrics

Clinical Success Rate

100.0%

Based on 4 completed trials

Completion Rate

100%(4/4)

Active Trials

1(20%)

Results Posted

0%(0 trials)

Phase Distribution

Ph not_applicable

20%

Ph phase_3

20%

Ph phase_4

60%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 3Large-scale testing

1(20.0%)

Phase 4Post-market surveillance

3(60.0%)

N/ANon-phased studies

1(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(4)

Detailed Status

Completed4

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 4

Trials by Phase

Phase 31 (20.0%)

Phase 43 (60.0%)

N/A1 (20.0%)

Trials by Status

recruiting120%

completed480%

Recent Activity

1 active trials

Showing 5 of 5

completedphase_4

Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus

NCT04260594

completedphase_4

The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection

NCT04252885

Clinical Trials (5)

Showing 5 of 5 trials

NCT03851991Phase 4

The Efficacy and Safety of Arbidol in Reducing the Frequency of AECOPD.

Completed

NCT03787459Phase 3

Severe Influenza Trial of ARbidol

Completed

NCT06462417Not Applicable

Efficacy and Safety of Arbidol in the Treatment of Allergic Rhinitis

Recruiting

NCT04260594Phase 4

Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus

Completed

NCT04252885Phase 4

The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection

Completed

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5